Pro-inflammatory cytokines and cytokine pathways

Pro-inflammatory cytokines are a diverse group of signaling proteins, such as Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), that are primarily secreted by immune cells like macrophages and T-lymphocytes to initiate and amplify the inflammatory response (StatPearls, 2023). These cytokines exert their effects by binding to specific high-affinity receptors on the surface of target cells, which triggers complex intracellular signaling pathways including the JAK-STAT, NF-kappaB, and MAPK cascades (Nature Reviews Immunology, 2018). The activation of these pathways leads to the transcription of genes that promote leukocyte recruitment, vascular permeability, and the production of additional inflammatory mediators (Frontiers in Immunology, 2021). While these processes are vital for host defense and wound healing, chronic or excessive cytokine production is a primary driver of tissue damage in autoimmune and autoinflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis (NIH, 2022). Consequently, these cytokines and their signaling components are major therapeutic targets, with drugs designed to neutralize ligands, block receptors, or inhibit downstream kinases (PubMed, 2020). However, because these pathways are essential for normal immunity, their pharmacological inhibition carries significant risks, most notably an increased susceptibility to opportunistic infections and potential long-term risks of malignancy (Journal of Clinical Investigation, 2019).

Other names

Inflammatory cytokinesPro-inflammatory mediatorsCytokine signaling cascadesInflammatory signaling pathways

Therapeutic intervention involves the neutralization of soluble cytokine ligands, competitive antagonism of cell-surface receptors, or the inhibition of intracellular signaling enzymes such as Janus kinases (JAKs) to prevent the transcription of inflammatory genes.